Study Comparing Different Neck Treatment Approaches in Patients With Oral Cancer Without Visible Neck Spread

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21-75
SponsorKolhapur Cancer Centre - Cancer Centers of America

About this trial

The goal of this clinical trial is to learn whether selective neck dissection involving lymph node levels I-III is as effective as selective neck dissection involving levels I-IV in treating adults with clinically node-negative (cN0) oral squamous cell carcinoma undergoing curative surgery. It will also evaluate whether extending the neck dissection to level IV affects cancer control, surgical complications, shoulder function, and quality of life. The main questions it aims to answer are:

* Does selective neck dissection of levels I-III provide regional recurrence-free survival comparable to selective neck dissection of levels I-IV? * Does extending the neck dissection to level IV improve overall survival, disease-free survival, or reduce regional recurrence? * Does selective neck dissection of levels I-III result in less postoperative morbidity, better shoulder function, and improved quality of life compared with selective neck dissection of levels I-IV?

Researchers will compare patients undergoing selective neck dissection of levels I-III with those undergoing selective neck dissection of levels I-IV to determine whether routine removal of level IV lymph nodes provides additional oncological benefit while maintaining acceptable functional outcomes.

Participants will:

* Undergo surgery for oral squamous cell carcinoma with random assignment to selective neck dissection of either levels I-III or levels I-IV. * Receive standard postoperative treatment, including radiotherapy or chemoradiotherapy when indicated according to the final pathology report. * Attend scheduled follow-up visits for clinical examinations and surveillance for cancer recurrence. * Undergo assessments of shoulder function, sensory function, postoperative complications, and quality of life using validated questionnaires at predefined follow-up intervals.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients aged over 21 years will be included.

Histologically proven squamous cell carcinoma of oral cavity will be included

Clinical stage T1-T4, N0, M0

cN0 neck on clinical examination and imaging (CT/MRI)

Disqualifiers

Recurrent cases

FNAC proven Positive cervical nodes

Patients with history of head and neck radiation therapy treatment

Previous neck surgery or radiotherapy

Trial design

Design model

Parallel

Treatments tested in this trial

  • Selective Neck Dissection (Levels I-IV)

    Procedure/Surgery

    Selective Neck Dissection (Levels I-IV)- Selective neck dissection (Levels I-IV) involves surgical removal of ipsilateral cervical lymphatic tissue from neck levels I, II, III, and IV during primary resection of oral squamous cell carcinoma in patients with a clinically node-negative (cN0) neck. The procedure is performed according to standard oncological principles with preservation of the spinal accessory nerve, internal jugular vein, and sternocleidomastoid muscle unless their sacrifice is required because of direct tumor involvement.

  • Intervention : Selective Neck Dissection (Levels I-III)

    Procedure/Surgery

    Selective neck dissection (Levels I-III) involves surgical removal of ipsilateral cervical lymphatic tissue from neck levels I, II, and III during primary resection of oral squamous cell carcinoma in patients with a clinically node-negative (cN0) neck. The procedure is performed according to standard oncological principles with preservation of the spinal accessory nerve, internal jugular vein, and sternocleidomastoid muscle unless their sacrifice is required because of direct tumor involvement.

Treatment groups

267 Participants
are divided into 2 treatment groups
Group A: Arm 1- Selective neck dissection involving cervical lymph node levels I, II, and III.Active comparator 1 intervention
Group B: Arm 2- Selective neck dissection level I, II, III and IVExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Regional recurrence free survival (RRFS)

Regional recurrence-free survival is defined as the time from the date of surgery to the first documented regional recurrence in the cervical lymph nodes or death from any cause, whichever occurs first. Participants without an event will be censored at the date of the last disease assessment.

Time frame
From the date of surgery to 3 years after surgery

Secondary outcomes

1

Overall Survival (OS)

Overall survival is defined as the time from the date of surgery to death from any cause. Participants who are alive at the time of the last follow-up will be censored on that date.

Time frame
From the date of surgery to 3 years after surgery.
2

Disease-Free Survival (DFS)

Disease-free survival is defined as the time from the date of surgery to the first documented recurrence of disease (local, regional, or distant), the occurrence of a second primary malignancy, or death from any cause, whichever occurs first. Participants without an event will be censored at the date of the last disease assessment.

Time frame
From the date of surgery to 3 years after surgery.
3

Occult Nodal Metastasis Rate

Occult nodal metastasis rate is defined as the proportion of participants with histopathologically confirmed cervical lymph node metastasis identified on final pathological examination despite a clinically node-negative (cN0) neck before surgery.

Time frame
Within 4 weeks after surgery (following final histopathological examination).
4

Patterns of Regional Nodal Failure

Patterns of regional nodal failure will be assessed by documenting the anatomical neck level(s), laterality, and timing of regional lymph node recurrence confirmed by clinical examination, imaging, or histopathological evaluation, and comparing their distribution between the two treatment groups.

Time frame
From the date of surgery to 3 years after surgery.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.